Atea Pharmaceuticals Inc. has announced that new data supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV) infection will be presented at The Liver Meeting® 2025, organized by the American Association for the Study of Liver Diseases (AASLD). The presentations will include results from a Phase 2 study evaluating the combination's multi-scale HCV modeling outcomes and viral resistance analysis, as well as findings from a Phase 1 study on the potential food effect with the fixed-dose combination. The abstracts will be available on the AASLD website following the embargo lift on October 7, 2025, and the meeting will take place November 7-11, 2025, in Washington, DC. Following the event, Atea will host a virtual investor meeting featuring hepatology and HCV experts to discuss the current treatment landscape and the ongoing global Phase 3 clinical development of the regimen.